Navigation Links
n-3 PUFAs Reduce Mortality and Hospital Admissions in Patients With Symptomatic Heart Failure
Date:9/2/2008

1)

* Difference between groups statistically significant (adjusted analysis; adapted from reference 1)

The GISSI group initiated, designed and conducted the GISSI-HF trial following positive results of a post-hoc analysis of the GISSI-Prevenzione trial (see Notes to Editors) which demonstrated that a subgroup of post-myocardial infarction patients with left ventricular dysfunction had reduced all-cause mortality and hospitalisations with n-3 PUFAs (2).

The primary objectives of the GISSI-HF trial were to demonstrate whether n-3 PUFAs or rosuvastatin improved all-cause mortality or hospitalisations for cardiovascular reasons. Participants were first randomised to receive n-3 PUFAs vs placebo (ORT). A subset of study participants was further randomised to receive rosuvastatin vs placebo.

GISSI-HF-the second large-scale cardiovascular outcome trial of n-3 PUFAs-also confirmed and further supports the safety of n-3 PUFAs, whose cardiovascular benefit in post- myocardial infarction patients had been established by the GISSI-Prevenzione trial (3). Accordingly, current indications of n-3 PUFAs are secondary prevention in post-myocardial infarction patients and treatment of hypertriglyceridaemia. Ongoing studies of n-3 PUFAs in other cardiovascular indications may unveil additional benefits in patients with cardiovascular diseases.

Professor Clemens Von Schacky, Head of Preventive Cardiology, University of Munich, Germany, also reviewed the GISSI-HF trial outcomes and presented the implications of these results for clinical practice during a Solvay-sponsored symposium at ESC 2008. He commented. "Very recently, we have seen a number of large outcome trials in congestive heart failure using a variety of approaches. Unfortunately, these were either neutral or negative. In sharp contrast, GISSI-HF, a meticulously conducted trial, reported the safety and efficacy of n-3 PUFAs in this patient population. Thus, evidence has been provided for guid
'/>"/>

SOURCE Solvay Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Prasugrel Head-to-Head Study Showed Reduced Cardiovascular Events in Diabetes Patients by 30 Percent Compared with Clopidogrel
2. National Study Shows Magnesium Sulfate Reduces Risk of Cerebral Palsy in Premature Births
3. Bad News to Bad Bugs: Northern Antibiotics Develops Novel Polymyxins With Reduced Toxicity
4. DaVita Strives to Improve Quality of Life and Reduce Overall Costs of Kidney Care Through Community-Based Education
5. New Study: Pine Bark Significantly Reduces Menstrual Pain
6. ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies
7. Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study
8. Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes
9. The Largest Ever Study of Diabetes Shows Intensive Glucose Control Reduces Serious Complications
10. CellCept(R) and a Reduced Level of CNI Shows Trend Towards Preservation of Kidney Function Versus a Standard-Dose CNI
11. Data Show Rufinamide, an Investigational Adjunctive Treatment for Lennox- Gastaut Syndrome, Reduced Drop Attacks by More Than 40%
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... , Oct. 1, 2014   Intarcia Therapeutics, Inc. ... its four phase 3 clinical trials for ITCA 650 ... matchstick-sized, subcutaneous osmotic mini-pump). The first trial, FREEDOM-1, was ... the efficacy and safety of ITCA 650 in patients ... ITCA 650 to be significantly superior to placebo for ...
(Date:10/1/2014)... , Oct. 1, 2014 The ... available. Interested parties can learn about the ... Health is supporting the health care continuum ... . Photo- http://photos.prnewswire.com/prnh/20140930/149504-INFO ... financials and the chief executive officer,s letter ...
(Date:10/1/2014)... 2014  Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), ... technology used to develop and produce enzymes and ... and industrial enzymes industries, today announced the receipt ... for commercial scale production of Abengoa,s proprietary cellulase ... under Abengoa,s license agreement with Dyadic. ...
Breaking Medicine Technology:Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 2Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 5Cardinal Health 2014 Digital Report to Shareholders Now Available 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 3
... Celldex also receives approval from Health Canada to ... collaboration with the National Cancer Institute, PHILLIPSBURG, ... the U.S. Food and Drug Administration (FDA) has,granted ... treatment of,EGFRvIII expressing Glioblastoma Multiforme (GBM). GBM is ...
... Jim Vandehei and John Harris ... The Politico, WASHINGTON, Dec. 6 , ... West Wing, 10:35 A.M. EST Q It,s an interesting time, ... on Capitol Hill right now.,But I,d love -- I mean, I,d love your overall assessment from -- ...
Cached Medicine Technology:Celldex Therapeutics Announces Orphan Drug Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma Multiforme 2Celldex Therapeutics Announces Orphan Drug Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma Multiforme 3Celldex Therapeutics Announces Orphan Drug Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma Multiforme 4Celldex Therapeutics Announces Orphan Drug Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma Multiforme 5Interview of the Vice President 2Interview of the Vice President 3Interview of the Vice President 4Interview of the Vice President 5Interview of the Vice President 6Interview of the Vice President 7Interview of the Vice President 8Interview of the Vice President 9Interview of the Vice President 10Interview of the Vice President 11Interview of the Vice President 12Interview of the Vice President 13Interview of the Vice President 14Interview of the Vice President 15Interview of the Vice President 16
(Date:10/2/2014)... Dennis Thompson HealthDay ... Forty-two states and the District of Columbia now have a ... respiratory illness that has been infecting children since the ... with the virus have died in recent weeks, but it,s ... played in those deaths, officials said. Health officials are ...
(Date:10/1/2014)... today in the Journal of the American Medical ... years with moderate or severe chronic knee pain, acupuncture ... University of Melbourne randomly assigned 282 patients (50 years ... or sham or pretend laser treatment. , Treatments ... blinded to laser and sham (inactive) laser acupuncture. , ...
(Date:10/1/2014)... that encourages people to keep their "eyes on the ... exercise. When walking, staying focused on a specific target ... and help people walk there faster, psychology researchers have ... while looking around the environment naturally, offers a new ... are less interested in exercise if physical activity seems ...
(Date:10/1/2014)... Lifeinsurance-policy.com has released a new ... insurance prices for smokers. , Smoking will always have ... quotes is the best method to find affordable coverage. ... who need coverage. , Whole life insurance premiums ... policy. Since the coverage is permanent, the initial ...
(Date:10/1/2014)... October 01, 2014 Join the more than ... Disorder Treatment Center’s first ever charity golf tournament to benefit ... with eating disorders who cannot afford treatment. The tournament will ... in Eureka, Mo. , The day-long event starts with ... reception and award dinner will begin at 5 p.m. and ...
Breaking Medicine News(10 mins):Health News:42 States Reporting Respiratory Virus That Targets Kids 2Health News:42 States Reporting Respiratory Virus That Targets Kids 3Health News:Study finds acupuncture does not improve chronic knee pain 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3
... at PA Velodrome BREINIGSVILLE, Pa., April 26 In just ... Paradysz bested the 24-hour track record at the Valley ... a new record of 416.09 miles (669.63 kilometers) biked in ... was set in 1980. Paradysz undertook this daunting physical challenge ...
... A team of scientists at The Campbell Family ... Hospital and international collaborators have discovered how to trigger ... included in new clinical trials that use a patient,s ... online today in Nature Medicine (DOI: 10.1038/nm.1953), ...
... found they also reduced chances of erectile dysfunction , , ... statins help prevent prostate cancer and reduce the risk ... there seems to be mounting evidence that there may ... treatment or prostate cancer prevention," said Dr. Lionel L. ...
... Inc. and the California Family Health Council have released a statewide ... ... (PRWEB) April 26, 2009 -- ISIS, Inc., has partnered with the ... Health (CDPH), STD Control Branch, to launch a statewide text messaging ...
... statins may reduce inflammation in prostate tumors, possibly hindering ... in the Duke Prostate Center. , "Previous studies have ... lower incidence of advanced prostate cancer, but the mechanisms ... largely unknown," said Lionel Baez, M.D., a researcher in ...
... red under blue light allows physicians to more easily ... which these cancers come back, says a Mayo Clinic ... international clinical trial. , VIDEO ALERT: Additional audio and ... Lance Mynderse describing the research, are available on the ...
Cached Medicine News:Health News:Father Breaks Cycling Record To Honor Daughter's Fight Against Lupus 2Health News:Scientists discover how to improve immune response to cancer at Princess Margaret Hospital 2Health News:Statins Guard Against Prostate Cancer 2Health News:Statins Guard Against Prostate Cancer 3Health News:Statins Guard Against Prostate Cancer 4Health News:HookUp: Sexual Health Info Text Messaging Service for California Youth Launches 2Health News:Statins may exert influence on prostate cancer growth by reducing inflammation 2Health News:Mayo Clinic researcher says improved detection of bladder tumors reduces cancer recurrence 2Health News:Mayo Clinic researcher says improved detection of bladder tumors reduces cancer recurrence 3
5 mm tying platform. Round knurled handle with dull finish. Straight shafts. Overall length 3.9 inches....
Curved shafts with 12 mm tying platform. Serrated handle with polished finish. Overall length 4.3 inches....
Hartman Mosquito forceps, size 10 cm and made of Japanese S.S ....
Hartman Mosquito forceps, straight serrated jaws, ring handle, dull finish, overall length 75 mm....
Medicine Products: